Antibody-Drug Conjugates (ADCs): Successes in Targeted Cancer Therapy

ADCs are a new class of drugs used to treat cancer. They combine a monoclonal antibody with a cytotoxic drug. The antibody seeks out and binds to specific molecules on cancer cells. Once attached, the ADC releases the cytotoxic drug, killing the cancer cell. This approach reduces the harm to healthy cells compared to traditional chemotherapy.

Approved ADCs and Their Impact

Several ADCs have been approved for treating various cancers. Here are some examples:

  • Brentuximab vedotin treats Hodgkin lymphoma and anaplastic large cell lymphoma.
  • Trastuzumab emtansine targets HER2-positive breast cancer.
  • Enfortumab vedotin is a new option for advanced bladder cancer.

These drugs have improved treatment outcomes for many patients.

Approved ADCs in clinical use.

Promising Candidates in Late-Stage Trials

The success of current ADCs has led to the development of more. Here are some examples of drugs in late-stage clinical trials:

  • Sacituzumab govitecan targets multiple cancers, including metastatic triple-negative breast cancer.
  • Polatuzumab vedotin shows promise for treating diffuse large B-cell lymphoma.

Structure of sacituzumab govitecan

Optimizing ADCs for the Future

Researchers are constantly improving ADCs by focusing on:

  • More effective antibodies
  • Improved linkers between the antibody and drug
  • More potent cytotoxic drugs

Additionally, researchers are exploring new targets for ADCs and combining them with other therapies like immunotherapy.

Researchers at leading institutions and companies, alongside reliable suppliers of high-quality research reagents (like Maxanim), are constantly innovating to develop more effective and specific ADCs.

Schematic representation of an ADC. The three basic components of an ADC are shown: antibody, payload, and linker. In addition, different alternatives of those components in anti-HER2 ADCs are illustrated. 

Conclusion

ADCs are a valuable tool in fighting cancer. Approved drugs and those in development offer more targeted and effective treatments for patients. Continued research will lead to even better ADCs in the future.


in News
Antibody-Drug Conjugates (ADCs): Successes in Targeted Cancer Therapy
Gen store June 20, 2024
Share this post
Tags
Archive
Sign in to leave a comment
Antibody-Drug Conjugates (ADCs): Targeted Cancer Therapy